نتایج جستجو برای: non small cell lung cancer nsclc

تعداد نتایج: 4070744  

2017
Yijun Tian Qian Liu Kongju Wu Qian Chu Yuan Chen Kongming Wu

Non-small cell lung cancer (NSCLC) consists of several subtypes, including adenocarcinoma, squamous cell lung cancer, large cell lung cancer, and other rarer types. Platinum-based regimens are currently the standard for treatment of advanced NSCLC. Nedaplatin is reportedly associated with a high response rate in squamous cell lung cancer. However, the relevant studies are small and mainly descr...

2017
Justin Goodwin Michael L Neugent Shin Yup Lee Joshua H Choe Hyunsung Choi Dana M R Jenkins Robin J Ruthenborg Maddox W Robinson Ji Yun Jeong Masaki Wake Hajime Abe Norihiko Takeda Hiroko Endo Masahiro Inoue Zhenyu Xuan Hyuntae Yoo Min Chen Jung-Mo Ahn John D Minna Kristi L Helke Pankaj K Singh David B Shackelford Jung-Whan Kim

Adenocarcinoma (ADC) and squamous cell carcinoma (SqCC) are the two predominant subtypes of non-small cell lung cancer (NSCLC) and are distinct in their histological, molecular and clinical presentation. However, metabolic signatures specific to individual NSCLC subtypes remain unknown. Here, we perform an integrative analysis of human NSCLC tumour samples, patient-derived xenografts, murine mo...

Journal: :Journal of Physics D 2021

Abstract Non-small cell lung cancer (NSCLC) is the most common type of cancer, with 85% all reported as NSCLC. Moreover, there are no effective treatments in advanced This study shows for first time that oral administration plasma-treated water (PTW) can cure The cold plasma generates a cocktail reactive species, and this to mice showed toxicities even at highest dose PTW, after single repeated...

2011
Shih-Chieh Chang Cheng-Yu Chang Jin-Yuan Shih

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) cases comprise approximately 85% of the lung cancer cases. Before the era of target therapy, platinum-based doublet chemotherapy only led to a median survival of 8-9 months and a one-year survival of 30%-40% in patients with advanced NSCLC. In July 2002, gefitinib, a small-molecule epidermal ...

2016
Ming-Ming Wei Guang-Biao Zhou

As a leading cause of cancer deaths worldwide, lung cancer is a collection of diseases with diverse etiologies which can be broadly classified into small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Lung cancer is characterized by genomic and epigenomic alterations; however, mechanisms underlying lung tumorigenesis remain to be elucidated. Long non-coding RNAs (lncRNAs) are a...

Journal: :Onkologie 1984
O Kokron

Non-small cell lung cancer (NSCLC) is less responsive to chemo- and radiotherapy than bronchogenic small cell cancer. Until now the results of chemotherapy in NSCLC have been disappointing. In a retrospective study on epidermoid cell lung cancer we can show that there is no increase of the survival time during the last 22 years. In a total of 2425 patients the median survival time ranged from 1...

Journal: :Journal of Thoracic Oncology 2022

Patients with programmed death-ligand 1 positive (PD-L1+), locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) have a poor prognosis and treatment options are limited. Sitravatinib, selective tyrosine kinase inhibitor, reduces the number of myeloid-derived suppressor cells regulatory T cells, promotes expansion migration antitumor cytotoxic increases ratio M1/M2-pola...

Journal: :medical hypothesis, discovery and innovation ophthalmology journal 0
sofia lampaki pulmonary deparment-oncology unit, ``g. papanikolaou`` general hospital, aristotle university of thessaloniki, thessaloniki, gree ioannis kioumis pulmonary deparment-oncology unit, ``g. papanikolaou`` general hospital, aristotle university of thessaloniki, thessaloniki, greece georgia pitsiou pulmonary deparment-oncology unit, ``g. papanikolaou`` general hospital, aristotle university of thessaloniki, thessaloniki, greece george lazaridi oncology department, ``g. papageorgiou`` hospital, thessaloniki, greece konstantinos syrigos oncology department, ``sotiria`` hospital of chest diseases, university of athens, athens, greece georgia trakada department of clinical therapeutics, division of pneumonology, medical school, national university of athens, athens, greece

it has been observed that lung cancer either non-small cell or small cell is responsible for eye metastases. this form of metastases in several cases was the first manifestation of the disease and further investigation led to the diagnosis of the underlying malignancy. both types of lung cancer are equally responsible for this demonstration. furthermore; both chemotherapy and tyrosine kinase in...

Journal: :Journal of Thoracic Oncology 2021

A rapidly increasing number of oncogenic drivers have been identified in non-small cell lung cancer (NSCLC) which has led to a shift towards next generation sequencing (NGS)-based testing as sequential single-gene is not feasible due limited biopsy material and high frequency depletion samples. However, NGS costly the turnaround time often longer than what suitable for clinical decision making....

2013
Xin-Feng Chen Meng Wang Dong-Li Yue Jin-Yan Liu Lan Huang Feng Li Song Zhao Yu Qi Wei Hu Xiang-Nan Li Yi Zhang

Background Lung cancer is the most common cause of cancer-related mortality worldwide. Survival rates after non-small cell lung cancer (NSCLC) diagnosis still remain poor, despite standardization of surgery and adjuvant treatment. Cancer testis (CT) antigens as targets for immunotherapy in cancer patients have been heavily investigated. We aim to evaluate the expression of CT antigens in non-sm...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید